Down syndrome hyperactivity drug trial stalls after just 3 kids enrolled
NCT ID NCT06042257
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug guanfacine to see if it could reduce hyperactivity and impulsivity in children aged 6 to 12 with Down syndrome. The plan was to give the drug or a placebo for 8 weeks and measure behavior changes. However, the trial was stopped early after only 3 children joined, so we don't have enough data to know if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guanfacine (immediate-release capsules)
What this could lead to
If it had worked, this could have pointed toward a medication to ease hyperactivity and impulsivity in children with Down syndrome.
What could go wrong
The trial was terminated early with only 3 participants, so no reliable conclusions can be drawn. Guanfacine may also cause side effects like drowsiness or low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERACTIVITY IN CHILDREN WITH DOWN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akron Children's Hospital
Akron, Ohio, 44308, United States
-
Ann and Robert H. Lurie Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Atrium Health-Wake Forest School of Medicine
Charlotte, North Carolina, 28204, United States
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
-
Duke University Hospital
Durham, North Carolina, 27705, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Kennedy Krieger Institute
Baltimore, Maryland, 21205, United States
-
Massachusetts General Hospital
Lexington, Massachusetts, 02421, United States
-
Phoenix Childrens Hospital
Phoenix, Arizona, 85016, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
University of Wisconsin Madison
Madison, Wisconsin, 53792, United States
-
Virginia Center for Children
Richmond, Virginia, 23220, United States